In 1950, Boehringer Ingelheim’s prescription medicine business came into being on the Canadian market. As the company had still not established its own affiliate in Canada, Boehringer Ingelheim products were marketed under licence in cooperation with Geigy.
The foundation of Boehringer Ingelheim’s own country organisation with offices in Montreal and Quebec took place in 1972. Since 1978, the main office has been in Burlington (Ontario). At the end of 2011, over 780 employees worked for Boehringer Ingelheim in Canada; they are the mainstay of its success. Besides marketing prescription medicines, over-the-counter medications and animal health products, the Canadian company has also devoted itself to research.
In 1988, a research centre was acquired in Laval that was expanded in 1997 and 2007. There, some 160 scientists undertake research into novel antiviral substances. They have the use of state-of-the-art technology to add to their specialist know-how. The target is the development of new therapeutic solutions for acute and chronic viral diseases.
Among others, efforts are directed towards the therapeutic areas HIV, the prevention and therapy of cytomegalovirus (CMV), part of the herpes family.
In medicine marketing, Spiriva® and Micardis® are very successful and are the biggest Boehringer Ingelheim products on the Canadian pharmaceutical market, which is among the ten largest in the world.
The new oral anticoagulant with the active ingredient dabigatran etexilate is registered in Canada under the brand name Pradaxa® for stroke prevention in patients with atrial fibrillation. Twynsta® and the diabetes treatment Trajenta® have also been launched on the market.